Manufacturing and Supply Chain Publications 

Overcoming CMC, manufacturing, and supply chain challenges in vaccine production: a review of efforts in the Global South, with a focus on Africa. Vishal Sonje and Valerie Chambard. Vaccine Insights 2025, 4(4) 89-100.  https://www.insights.bio/vaccine-insights/journal/article/3522/overcoming-cmc-manufacturing-and-supply-chain-challenges-in-vaccine-production-a-review-of-efforts-in-the-global-south-with-a-focus-on-africa

Fast-Tracking Vaccine Manufacturing: CEPI’s Rapid Response Framework for the 100 Days Mission. Kim J, Sabet-Azad R, Patel D' Malin G, Askary SH, Särnefält A. Vaccines 2025, 13, 849. https://doi.org/10.3390/vaccines13080849

The Platform Readiness Dashboard: A Tool for Evaluating Vaccine Platform Suitability for a Rapid Response to Epidemic and Pandemic Threats. Sabet-Azad R, Hoath C, Bézay N, Särnefält A. Vaccines 2025, 13, 793. https://doi.org/10.3390/vaccines13080793

Seven unresolved questions for vaccine science in 2025. Ingrid Kromann et al. Vaccine Insights March 2025, 4(1), 31–36. https://www.insights.bio/vaccine-insights/journal/article/3443/seven-unresolved-questions-for-vaccine-science-in-2025

Advancing local manufacturing capacities for vaccines within Africa – Opportunities, priorities and challenges. Doua J, Ndembi N, Auerbach J et al. ELSEVIER Vaccine, Volume 50, 19 March 2025. https://doi.org/10.1016/j.vaccine.2025.126829

Advanced technologies enabling accessible and sustainable vaccine development and manufacturing for future pandemics. June Kim and Anna Särnefält. Vaccine Insights 2024, 3(7) 119-136. https://www.insights.bio/vaccine-insights/journal/article/3326/Advanced-technologies-enabling-accessible-and-sustainable-vaccine-development-and-manufacturing-for-future-pandemics

A Strategic Guide to Improve and De-risk Vaccine Development: CEPI’s CMC Framework. Anna Sarnefalt, Ranna Eardley-Patel, Diletta Magini, et al. Journal of Pharmaceutical Science and Technology July 2024, Vol 78, issue 4.  https://journal.pda.org/content/early/2024/07/25/pdajpst.2023.012912

Stability Preparedness: The Not-So-Cold Case for Innovations in Vaccine Stability Modelling and Product Release. Franz Schnetzinger, et al. Vaccines 2024, 12(9) https://www.mdpi.com/2076-393X/12/9/1000

Improving vaccine equity by increasing vaccine thermostability. Renske Hesselink et al. Science Translational Medicine, 24 Jul 2024, Vol 16, Issue 757. https://www.science.org/doi/10.1126/scitranslmed.adm7471

The 100 Days Mission: how a new medical-countermeasures network can deliver equity and innovation. Ranna Eadrley-Patel et al. The Lancet October 2023, Volume 402, Issue 10412 p1507-1510. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01775-0/abstract

Availability and use of Standards in vaccine development. Ingrid Kromann, Anna Särnefält et al. npj Vaccines 8, 95 June 2023.  https://www.nature.com/articles/s41541-023-00692-0

Accelerating the development of vaccine microarray patches for epidemic response and equitable immunization coverage requires investment in microarray patch manufacturing facilities. Renske Hesselink et al. Expert Opinion on Drug Delivery, 20(3), 315–322.  https://www.tandfonline.com/doi/full/10.1080/17425247.2023.2168641

Vaccine manufacturing: the future is global. Matthew Downham. Vaccine Insights 2022, 1(6) 293-298. https://www.insights.bio/vaccine-insights/journal/article/2659/Vaccine-manufacturing-the-future-is-global

Sustainable vaccine manufacturing in low- and middle-Income countries. Matthew Downham, et al. Vaccine, Vol 40, Issue 50, Nov 2022 pp 7288-7304. https://www.sciencedirect.com/science/article/abs/pii/S0264410X22013056?via%3Dihub 

Analytical development for rapid response vaccines: start early, think ahead. Sarnefalt, A and Kromann, I. Vaccine Insights 2022; 1(1), 1–3. http://dx.doi.org/10.18609/vac.2022.001

Considerations for the stability of vaccines as liquid-, frozen-, or lyophilized presentations. Ramin Sabet Azad, Raafat Fahim. Vaccine Insights 2022; 1(5), 241–245 https://www.insights-test.bio/vaccine-insights/journal/article/2614/Considerations-for-the-stability-of-vaccines-as-liquid-frozen-or-lyophilized-presentations